Recent Digestion Is...
Health Care: Drugs
Meridian Bioscience Inc. (VIVO: NASDAQ)
$18.05 0.00 | 0.00%
02/08/12 - 02:35 PM ET
112.32K / 225.50K
Vol / Avg. Vol:18.06 / 18.05
Open / Prev. Close:18.05 - 18.19
Today's Range:14.81 - 27.37
52 Wk Range:-4.19%
Performance YTD:TheStreet Rating:
Portfolios with VIVO
- Portfolio NameUser Type
- ContributorHighest-Yielding Drug Stocks
- Userhulkkims Portfolio 1
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE 20 Dividend Stoc...
- UserSUPRATRADE HOT STOCKS (BUY ...
- ContributorDividend Stocks for the Wee...
- Userrussbow98 Portfolio 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- UserVinay's Long Term Investmen...
Latest VIVO Headlines from TheStreet
- Meridian Bioscience Rises On Unusually High Volume (VIVO) 02.01.12 | 03:02 pm
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 01.31.12 | 09:01 am
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 11.16.11 | 10:11 am
- Meridian Bioscience Stock Hits New 52-Week Low (VIVO) 10.03.11 | 09:10 am
- Meridian Bioscience Stock Hits New 52-Week Low (VIVO) 09.21.11 | 02:09 pm
- Meridian Bioscience Stock Hits New 52-Week Low (VIVO) 08.19.11 | 03:08 pm
- Meridian Bioscience Inc. Stock Downgraded (VIVO) 08.16.11 | 07:08 am
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 07.27.11 | 09:07 am
- Meridian Bioscience Stock Hits New 52-Week High (VIVO) 07.15.11 | 10:07 am
- Meridian Bioscience Reaches New 52-Week High (VIVO) 07.07.11 | 09:07 am
Press Releases for VIVO
- Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2012 Guidance - Business Wire 01.25.12 | 07:01 am
- Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker - Business Wire 01.18.12 | 07:01 am
- Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. Difficile GDH Test - Business Wire 12.27.11 | 11:12 am
- Meridian Bioscience Receives FDA Clearance For New Molecular Test: Illumigene® Group B Streptococcus - Business Wire 12.12.11 | 09:12 am
- Meridian Bioscience Reports Fourth Quarter And Full-Year 2011 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2012 Guidance - Business Wire 11.10.11 | 07:11 am
- Meridian Bioscience Provides Sales And Earnings Guidance For Fiscal 2012 And Comments On Fiscal 2011 Guidance - Business Wire 08.25.11 | 11:08 am
- Meridian Bioscience Establishes Direct Sales In Australia Through Bioline Australia - Business Wire 08.23.11 | 01:08 pm
- Meridian Bioscience Launches ImmunoCard® C. Difficile GDH Assay In Europe - Business Wire 08.09.11 | 03:08 pm
- Meridian Bioscience Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Revises Fiscal 2011 Guidance - Business Wire 07.21.11 | 06:07 am
- Meridian Tests Detect Deadly Toxins Produced By E. Coli O104 Outbreak Strain - Business Wire 06.10.11 | 12:06 pm
Partner Headlines for VIVO
- UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform - Benzinga 01.31.12 | 09:01 am
- Dividend Stocks That Combine Growth And Income - Seeking Alpha 01.20.12 | 08:01 am
- FDA OKs Meridian's GDH Test - Analyst Blog - Zacks 01.05.12 | 10:01 am
- 30 'Overdue' Dividend Increases -- Will History Repeat Itself? - Seeking Alpha 08.19.11 | 06:08 pm
- FDA OKs Meridian C. difficile Test - Analyst Blog - Zacks 05.13.11 | 09:05 am
- Meridian Bioscience: An Overvalued Dividend Contender - Seeking Alpha 04.12.11 | 06:04 am
- MF GLOBAL HLDGS (MF) - Profit Tracks - Zacks 02.10.11 | 01:02 am
- UPDATE 1-Meridian Bioscience Q1 misses Street view - Reuters 01.20.11 | 08:01 am
- Dividend Growth and the S&P 500 - Seeking Alpha 01.18.11 | 06:01 am
- Cramer's Lightning Round - Revlimid Is Still a Miracle Drug (12/6/10) - Seeking Alpha 12.07.10 | 07:12 am
